Chemoprevention of colorectal cancer in ulcerative colitis

Victoria J. Croog, Thomas A. Ullman, Steven H. Itzkowitz

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population. Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. Efforts to reduce this risk have focused on colonoscopic surveillance as the best alternative to the more definitive, but less appealing, approach of prophylactic colectomy. However, spurred on by findings in the sporadic CRC literature, there has been a growing interest in a possible role for chemoprevention of CRC in patients with UC. Empirical Studies: Published evidence to date indicates that 5-aminosalicylic acid agents are protective against the development of dysplasia and CRC. Oral, but not topical, steroids also appear to be chemoprotective, but their chronic use cannot be recommended for this indication. Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis. Evidence suggests, but does not prove, that folic acid is chemopreventive in patients with UC. Further studies are needed to fully define the chemoprotective role of these and other agents.

Original languageEnglish (US)
Pages (from-to)392-400
Number of pages9
JournalInternational Journal of Colorectal Disease
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Chemoprevention
Ulcerative Colitis
Colorectal Neoplasms
Sclerosing Cholangitis
Protective Agents
Mesalamine
Ursodeoxycholic Acid
Colectomy
Folic Acid
Steroids
Population
Neoplasms

Keywords

  • 5-Aminosalicylic acid
  • Colorectal cancer
  • Folic acid
  • Ulcerative colitis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chemoprevention of colorectal cancer in ulcerative colitis. / Croog, Victoria J.; Ullman, Thomas A.; Itzkowitz, Steven H.

In: International Journal of Colorectal Disease, Vol. 18, No. 5, 01.09.2003, p. 392-400.

Research output: Contribution to journalArticle

Croog, Victoria J. ; Ullman, Thomas A. ; Itzkowitz, Steven H. / Chemoprevention of colorectal cancer in ulcerative colitis. In: International Journal of Colorectal Disease. 2003 ; Vol. 18, No. 5. pp. 392-400.
@article{684d9c303e7344de9133756ba6bb216f,
title = "Chemoprevention of colorectal cancer in ulcerative colitis",
abstract = "Background: Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population. Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. Efforts to reduce this risk have focused on colonoscopic surveillance as the best alternative to the more definitive, but less appealing, approach of prophylactic colectomy. However, spurred on by findings in the sporadic CRC literature, there has been a growing interest in a possible role for chemoprevention of CRC in patients with UC. Empirical Studies: Published evidence to date indicates that 5-aminosalicylic acid agents are protective against the development of dysplasia and CRC. Oral, but not topical, steroids also appear to be chemoprotective, but their chronic use cannot be recommended for this indication. Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis. Evidence suggests, but does not prove, that folic acid is chemopreventive in patients with UC. Further studies are needed to fully define the chemoprotective role of these and other agents.",
keywords = "5-Aminosalicylic acid, Colorectal cancer, Folic acid, Ulcerative colitis, Ursodeoxycholic acid",
author = "Croog, {Victoria J.} and Ullman, {Thomas A.} and Itzkowitz, {Steven H.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1007/s00384-002-0476-6",
language = "English (US)",
volume = "18",
pages = "392--400",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Chemoprevention of colorectal cancer in ulcerative colitis

AU - Croog, Victoria J.

AU - Ullman, Thomas A.

AU - Itzkowitz, Steven H.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background: Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population. Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. Efforts to reduce this risk have focused on colonoscopic surveillance as the best alternative to the more definitive, but less appealing, approach of prophylactic colectomy. However, spurred on by findings in the sporadic CRC literature, there has been a growing interest in a possible role for chemoprevention of CRC in patients with UC. Empirical Studies: Published evidence to date indicates that 5-aminosalicylic acid agents are protective against the development of dysplasia and CRC. Oral, but not topical, steroids also appear to be chemoprotective, but their chronic use cannot be recommended for this indication. Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis. Evidence suggests, but does not prove, that folic acid is chemopreventive in patients with UC. Further studies are needed to fully define the chemoprotective role of these and other agents.

AB - Background: Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population. Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. Efforts to reduce this risk have focused on colonoscopic surveillance as the best alternative to the more definitive, but less appealing, approach of prophylactic colectomy. However, spurred on by findings in the sporadic CRC literature, there has been a growing interest in a possible role for chemoprevention of CRC in patients with UC. Empirical Studies: Published evidence to date indicates that 5-aminosalicylic acid agents are protective against the development of dysplasia and CRC. Oral, but not topical, steroids also appear to be chemoprotective, but their chronic use cannot be recommended for this indication. Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis. Evidence suggests, but does not prove, that folic acid is chemopreventive in patients with UC. Further studies are needed to fully define the chemoprotective role of these and other agents.

KW - 5-Aminosalicylic acid

KW - Colorectal cancer

KW - Folic acid

KW - Ulcerative colitis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0041353949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041353949&partnerID=8YFLogxK

U2 - 10.1007/s00384-002-0476-6

DO - 10.1007/s00384-002-0476-6

M3 - Article

VL - 18

SP - 392

EP - 400

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 5

ER -